(C) Reuters. Up More Than 16% in the Last Month, is QuantumScape Still a Buy?
Shares of lithium battery developer QuantumScape (QS) soared last week on the news that it has partnered with a large automaker. However, is it wise to bet on the stock even though smart money interest has declined lately? Let’s find out.Solid-state lithium-metal batteries developer QuantumScape Corporation (QS) made its stock market debut in November 2020 via special purpose acquisition company (SPAC) Kensington Capital Acquisition Corp. QS is backed by investors such as Volkswagen AG (OTC:VWAGY) and Bill Gates. Its shares have soared 16% over the past month. The stock rallied 26.6% last week primarily because of the company’s announcement on September 21 that it has partnered with an undisclosed large automaker to evaluate prototypes of its solid-state battery cells.
However, the stock has lost 15% over the past three months and 40% over the past six months. QS’ loss from operations increased 248.8% year-over-year to $49.62 million for the second quarter ended June 30, 2021, while its loss per share came in at $0.12, up 100% year-over-year. According to an SEC filing, the company’s Director Justin Mirro sold 20,000 shares on September 7. Hedge funds look less bullish about the stock lately. Moreover, QS is not expected to begin commercial production until 2024. So, the stock’s near-term prospects look bleak.
Here’s what could influence QS’ performance in the near term:
Up More Than 16% in the Last Month, is QuantumScape Still a Buy?
By Reuters – Sep 29, 2021
By Jason Lange, Megan Davies and David Randall WASHINGTON (Reuters) -A standoff in Washington between President Joe Biden’s Democrats and Republicans is threatening to trigger a…
By Investing.com – Sep 29, 2021
By Yasin Ebrahim
Investing.com – The S&P 500 climbed Wednesday, attempting to claw back some losses from a day earlier, though ongoing concerns about the recovery and a potential…
By Reuters – Sep 29, 2021
By Deena Beasley (Reuters) -Laboratory studies show that Merck & Co’s experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of…
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.